MPO and colitis: TNBS-treated mice developed a moderate to severe colitis, as evidenced by elevated levels of the clinical activity score (Figure 7), the colon weight/length ratio, myeloperoxidase (MPO) activity (Figure 8) and pro-inflammatory cytokines (Figure 9).